<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161859</url>
  </required_header>
  <id_info>
    <org_study_id>P-20160020534</org_study_id>
    <nct_id>NCT04161859</nct_id>
  </id_info>
  <brief_title>Use of Nutraceuticals in Clinical Practice</brief_title>
  <official_title>Observational Study on the Use of the Nutraceutical With Cardio-metabolic Actions in the Patient in Primary and Secondary Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic
      actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended
      in the clinic. In particular the study will analyze how much the nutraceutical is prescribed
      and what are the purposes for which it is used and at what dosages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic
      actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended
      in the clinic. In particular the study will analyze how much the nutraceutical is prescribed
      and what are the purposes for which it is used and at what dosages. In particular, attention
      will be focused on the following substances: berberine (500-1000 mg/day), monacolin (5-10
      mg/day), phytosterols (0.9-1.8 g/day), resveratrol (100-500 mg/day), omega-3 (1-3 g/day),
      alpha lipoic acid (400-800 mg/day), curcumin (400 mg/day), psyllum (3.5 g/day), coenzyme Q10
      (100-200 mg/day), inositol (250-600 mg/day), glucomannan (1-4 g/day), chitosan (800-1200
      mg/day), guar fiber (10-20 g/day), L-arginine (250 mg/day).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of the use of nutraceutical in clinical practice</measure>
    <time_frame>From 2010 to 2015</time_frame>
    <description>Prevalence</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutraceutical</intervention_name>
    <description>Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic, or hypertensive or dyslipidemic patients in primary and secondary prevention
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diabetic patients in primary and secondary prevention or Hypertensive patients in primary
        and secondary prevention or Dyslipidemic patients in primary and secondary prevention

        Exclusion Criteria:

        Patients with hystory of malignancy, and significant neurological or psychiatric
        disturbances, including alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
    <phone>+390382502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
      <phone>+390382502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD, FESC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

